Amy Rothberg, clinical professor of internal medicine in the Division of Metabolism, Endocrinology and Diabetes at the University of Michigan, says it also helps improve outcomes in people with type 2 diabetes and cardiorenal (heart and kidney) conditions, similar to semaglutide
Urticaria, pruritus without rash, and angioedema have been reported in less than one percent of patients
Semaglutide mimics the GLP-1 hormone, which acts on appetite-regulating centres in the brain to reduce hunger and increase feelings of fullness after eating
Your doctor might recommend adjusting your dose or a different drug altogether
Choose Retatrutide If: Maximum weight loss is the primary goal Previous GLP-1 agonists produced significant nausea (GIP component may help) No specific liver health concerns requiring treatment Tolerance for slightly higher GI side effects during titration Response to dual agonists (like tirzepatide) has been positive Choose Survodutide If: Liver health concerns exist (fatty liver, MASH, elevated liver enzymes) Moderate weight loss goals rather than maximum efficacy priority Interest in potential cardiovascular outcome benefits (CVOT data pending) Preference for a compound with FDA Breakthrough Therapy designation Plans to potentially transition to approved medication once available For most people focused primarily on weight loss, Retatrutide presents the stronger option based on available data
